不同靶向药物治疗恶性黑色素瘤皮肤并发症发生率差异的网状Meta分析

发布时间：2018-04-02 23:34

本文选题：黑色素瘤　切入点：靶向药物　出处：《重庆医学》2017年12期

【摘要】：目的采用网状Meta分析方法比较5种靶向药物方案治疗恶性黑色素瘤的皮肤鳞癌和皮疹发生率差异。方法计算机检索PubMed和Cochrane Library数据库,检索范围从建库起至2015年11月。网状Meta分析将直接和间接比较的证据合并,评估5种靶向药物方案治疗恶性黑色素瘤的皮肤并发症发生率差异的合并比值比(OR)和累积排序概率。结果 6项随机对照试验符合纳入标准被纳入。结果表明:与达拉非尼+曲美替尼相比,维罗非尼在患者中皮肤鳞癌发生率相对较高(OR=9.20,95%CI=1.26~52.53),维罗非尼+罗氏替尼的皮疹发生率相对较高(OR=6.81,95%CI=1.01~41.87)。累积排名曲线下面积(SUCRA)值结果表明,采用曲美替尼的患者的皮肤鳞癌发生率最低,达拉非尼+曲美替尼的皮疹发生率最低。结论达拉非尼+曲美替尼对恶性黑色素瘤患者所产生的并发症发生率最低。
[Abstract]:Objective to compare the incidence of skin squamous cell carcinoma (SCC) and skin rash in malignant melanoma treated with five targeted drug regimens by reticular Meta analysis.Methods PubMed and Cochrane Library databases were searched by computer from the time of construction to November 2015.Reticular Meta analysis combined direct and indirect comparative evidence to assess the combination ratio and cumulative sequencing probability of the difference in the incidence of skin complications in the treatment of malignant melanoma with five targeted drug regimens.Results six randomized controlled trials were included according to the inclusion criteria.The results showed that the incidence of cutaneous squamous cell carcinoma (SCC) of Verofinil was higher than that of dalafenitinib. The incidence of skin squamous cell carcinoma was higher than that of telfinitinib. The incidence of rashes of Veropinib was relatively higher than that of telofinitinib. The incidence of skin squamous cell carcinoma was higher than that of telofinitinib. The incidence of skin squamous cell carcinoma was higher than that of telfinitinib.The results of SUCRA showed that the incidence of cutaneous squamous cell carcinoma was the lowest in patients with trimetazinib and the lowest in patients with telafenitinib.Conclusion Tarafinitinib has the lowest incidence of complications in patients with malignant melanoma.
【作者单位】：青岛大学医学院;费县人民医院皮肤科;青岛大学附属医院皮肤科;
【分类号】：R739.5

【相似文献】